Often, municipal corporations carry out flawed projects which go against public interest and only suit vested interests. Use of RTI can help unearth such irregularities. Here’s a startling example... The Mula-Mutha rivers in Pune resemble stinking nallahs, yet the Pune Municipal Corporation (PMC) had a brainwave of implementing a river navigation project on a 25-odd km stretch from Ramwadi to Kharadi, envisioning boat rides as one of the activities to save...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...

The government's decision to bust the price as well as monopoly of Bayer's anti-cancer drug, through the process of compulsory licensing now opens up the field for the generic industry to follow suit and could well pave the way for the availability of cheaper drugs for lifestyle diseases.  More generic companies could invoke the compulsory licensing clause of the Indian Patents Act, following Monday's decision to allow Natco Pharma to sell...

-The Hindu Business Line A Government report has called for enhancing investment in agriculture and leveraging technology to boost the country's farm sector growth in the years ahead. The report ‘State of Indian Agriculture 2011-12,' released by the Agriculture Ministry on Tuesday, called for institutional reforms in research set up to make it more accountable and geared towards delivery, conservation of natural resources such as water and land among others. “Achieving a 8-9...

In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...